Pay in 4 interest-free payments of $5.12 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Understanding your genetic peptide profile allows for more precise treatment planning, reducing trial-and-error adjustments that extend digestive side effects
It does not require encapsulation, a carrier molecule, or special formulation to maintain structural integrity in biological environments
Drug Interaction Studies With SOLIQUA 100/33 Insulin glargine and lixisenatide have no relevant potential to induce or inhibit CYP isozymes and, therefore, no direct drug interaction is expected
Each pen has 4 doses, so lasts 4 weeks
Funding to conduct this study was provided by Nestle Institute of Health Sciences
Individual response varies, so choose a time that helps you manage side effects most effectively
US$ 24.79
US$ 27.72
US$ 24.74
US$ 28.49
US$ 22.79
US$ 28.57
